We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
Read MoreHide Full Article
Insulet Corporation (PODD - Free Report) achieves a new milestone in Europe with its Omnipod Insulin Management System. The company announced that this system can now be used together with Novo Nordisk’s (NVO) Fiasp or Fast-Acting Insulin Aspart in Europe.
Per the press release, Fiasp has been tested and found safe for use in Insulet’s Omnipod System across Europe. Notably, Novo Nordisk’s Fiasp is the new-generation fast-acting insulin. This is claimed to enter the bloodstream twice faster compared with NovoRapid, another insulin analogue by Novo Nordisk. To note, NovoRapid starts to lower one’s blood sugar level 10 to 20 minutes after the patient takes it.
Needless to say, the super-fast Fiasp more closely matches a body’s insulin response to a meal, thereby improving glycemic control.
The addition of Fiasp for use along with the Omnipod System will significantly widen Omnipod’s scope. According to Insulet, it will provide additional option for both patients and prescribers to support their diabetes management needs. More specifically, Fiasp will provide a new alternative for diabetic patients, who require insulin to manage their post-meal sugar-level spikes.
Insulet is currently showcasing its Omnipod System at the European Association for the Study of Diabetes (EASD) annual meeting in Berlin, Germany (From Oct 1 to Oct 5). This is the first European conference for Insulet since the company initiated direct operations of Omnipod System product line in Europe.
Insulet’s Progress in Europe
Insulet became a direct seller of Omnipod System in Europe starting July 2018. The company is confident about the infrastructure and believes that it is well positioned to cash in on the rapidly-growing European customer base and the rising gross margin. In this context, Insulet has tied up with Glooko, Inc. Insulet aims at connecting its Omnipod System user data with Glooko+diasend.
The company announced plans of collaborating with the European Region of the International Diabetes Federation (IDF Europe) for regional advocacy activities. Notably, this partnership will provide a broader access to Insulet for closely engaging with the European diabetes community.
However, in the last reported quarter, revenues from international business were lower than the expected figure due to channel inventory in Europe. This also comprised a reduction of $7.4 million in revenues, thanks to the repurchase of the company’s inventory from the former European distributor. We believe that this latest development will act as an impetus lift to Omnipod’s performance in the region.
In this regard, going by a Research and Markets report published in CISION,the insulin market in the United States and Europe is projected to witness a CAGR of 6.17% (2016-2020).
Share Price Performance
Over the past three months, shares of Insulet have outperformed the industry it belongs to. The stock has rallied 14.7% compared with the industry’s 10.7% rise.
Zacks Rank & Key Picks
Insulet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Amedisys, Inc. (AMED - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock currently carries a Zacks Rank #2 (Buy).
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock is currently a Zacks #2 Ranked player.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
Insulet Corporation (PODD - Free Report) achieves a new milestone in Europe with its Omnipod Insulin Management System. The company announced that this system can now be used together with Novo Nordisk’s (NVO) Fiasp or Fast-Acting Insulin Aspart in Europe.
Per the press release, Fiasp has been tested and found safe for use in Insulet’s Omnipod System across Europe. Notably, Novo Nordisk’s Fiasp is the new-generation fast-acting insulin. This is claimed to enter the bloodstream twice faster compared with NovoRapid, another insulin analogue by Novo Nordisk. To note, NovoRapid starts to lower one’s blood sugar level 10 to 20 minutes after the patient takes it.
Needless to say, the super-fast Fiasp more closely matches a body’s insulin response to a meal, thereby improving glycemic control.
The addition of Fiasp for use along with the Omnipod System will significantly widen Omnipod’s scope. According to Insulet, it will provide additional option for both patients and prescribers to support their diabetes management needs. More specifically, Fiasp will provide a new alternative for diabetic patients, who require insulin to manage their post-meal sugar-level spikes.
Insulet is currently showcasing its Omnipod System at the European Association for the Study of Diabetes (EASD) annual meeting in Berlin, Germany (From Oct 1 to Oct 5). This is the first European conference for Insulet since the company initiated direct operations of Omnipod System product line in Europe.
Insulet’s Progress in Europe
Insulet became a direct seller of Omnipod System in Europe starting July 2018. The company is confident about the infrastructure and believes that it is well positioned to cash in on the rapidly-growing European customer base and the rising gross margin. In this context, Insulet has tied up with Glooko, Inc. Insulet aims at connecting its Omnipod System user data with Glooko+diasend.
The company announced plans of collaborating with the European Region of the International Diabetes Federation (IDF Europe) for regional advocacy activities. Notably, this partnership will provide a broader access to Insulet for closely engaging with the European diabetes community.
However, in the last reported quarter, revenues from international business were lower than the expected figure due to channel inventory in Europe. This also comprised a reduction of $7.4 million in revenues, thanks to the repurchase of the company’s inventory from the former European distributor. We believe that this latest development will act as an impetus lift to Omnipod’s performance in the region.
In this regard, going by a Research and Markets report published in CISION,the insulin market in the United States and Europe is projected to witness a CAGR of 6.17% (2016-2020).
Share Price Performance
Over the past three months, shares of Insulet have outperformed the industry it belongs to. The stock has rallied 14.7% compared with the industry’s 10.7% rise.
Zacks Rank & Key Picks
Insulet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Amedisys, Inc. (AMED - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock currently carries a Zacks Rank #2 (Buy).
Amedisys’ estimated long-term earnings growth rate is 19.4%. The stock holds a Zacks Rank of 2 at the moment. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock is currently a Zacks #2 Ranked player.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>